Marisa TaylorMike SpectorDan Levine
1/2
Eli Lilly logo is shown on one of the company s offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blake/File Photo
Read More
The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co (LLY.N) focused on alleged manufacturing irregularities and records tampering at a factory in Branchburg, New Jersey, that produces the pharmaceutical giantâs COVID-19 therapy and other drugs, three people familiar with the matter said.
The probe represents a significant escalation of the government scrutiny on Lilly. The pharmaceutical company, one of the world s largest, has been under examination for more than a year by the U.S. Food and Drug Administration over alleged manufacturing and records violations at the Branchburg factory.
Exclusive: U.S. opens criminal probe into alleged lapses at Eli Lilly plant - sources
By Marisa Taylor, Mike Spector and Dan Levine
Reuters
(Reuters) - The U.S. Justice Department has launched a criminal investigation into Eli Lilly and Co focused on alleged manufacturing irregularities and records tampering at a factory in Branchburg, New Jersey, that produces the pharmaceutical giant s COVID-19 therapy and other drugs, three people familiar with the matter said.
The probe represents a significant escalation of the government scrutiny on Lilly. The pharmaceutical company, one of the world s largest, has been under examination for more than a year by the U.S. Food and Drug Administration over alleged manufacturing and records violations at the Branchburg factory.
Exclusive: U S opens criminal probe into alleged lapses at Eli Lilly plant - sources reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Healthcare & PharmaceuticalsEXCLUSIVE Lilly hit by staff accusations, FDA scrutiny at COVID drug factories
Marisa TaylorDan Levine
9 minute read
An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar
Eli Lilly & Co (LLY.N) employees have accused a factory executive of altering documents required by government regulators in an effort to downplay serious quality control problems at the U.S. plant producing the drugmakerâs COVID-19 treatment, according to an internal Lilly complaint and a source familiar with the matter.
The unsigned report, filed April 8 in Lillyâs confidential employee complaint system and reviewed by Reuters, is the latest sign of manufacturing problems at the drug giant. The complaint asserts that the executive, a top quality official at the companyâs factory in Branchburg, New Jersey, rewrote findings by Lilly technical experts at the plant, which